1,523
Views
0
CrossRef citations to date
0
Altmetric
Editorial

What are the considerations for the pharmacotherapeutic management of acute promyelocytic leukemia in children?

, &
 

Declaration of Interest

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer Disclosures

One reviewer declares that their institution holds a US patent for the use of oral arsenic trioxide in the treatment of leukemia. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.

Additional information

Funding

The authors are supported by the American Italian Cancer Foundation Fellowship Program (to C Gurnari), as well as The Italian Foundation for Cancer Research (AIRC) 5 × 1000 project entitled “Metastatic disease: the key unmet need in oncology” to MYNERVA, award number 21267 (MYeloid NEoplasms Research Venture) as well The Ministry of Education, Universities and Research (MIUR), Italy through grant no. 2017WXR7ZT (to MT Voso).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.